De-Escalated Neoadjuvant Chemoimmunotherapy Shows Promise in Early TNBC

(MedPage Today)-Nivolumab (OPDIVO) is not associated with chemotherapy with improved pathological response rates (PCR) among patients with early negative negative breast cancer (TNBC), but a 12-week anti-mult in …